BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma)
Overview
BIA-ALCL is a T-cell non-Hodgkin lymphoma arising in or around the fibrous capsule surrounding a breast implant.
- First described in 1997 in a patient with recurring, treatment-resistant peri-implant effusion
- Median time from implant placement to diagnosis: 10 years
Pathogenesis
- Hypothesized: chronic T-cell inflammation from persistent bacterial biofilm on textured implant surface
- Implants implicated: textured implants (or patients with exposure to textured implants)
- Filling material (silicone vs. saline) does NOT seem to matter
- Almost always unilateral
Immunophenotype
- CD30 positive (densely)
- ALK negative (distinguishes from systemic ALCL)
- CD43 positive
- EBV negative
Board Pearl
BIA-ALCL is CD30+, ALK−, EBV−. Unlike systemic ALCL, ALK is negative. This immunophenotype is key to diagnosis.
Clinical Presentation
Effusion-Only (85%)
- Late-onset seroma (> 1 year after implant placement)
- More indolent course
- Implant + capsule removal = curative in most cases
- Prophylactically remove contralateral implant
Mass-Forming (15%)
- Palpable mass (15%) adjacent to prosthesis in affected breast
- More aggressive behavior
- If mass or distant disease confirmed → systemic treatment
Other presentations:
- Pain, skin lesions (erythema, subcutaneous nodules, ulcers)
- If implant contracture present: usually Grade III or IV contracture (visible/symptomatic)
- Distant disease and systemic “B” symptoms are rare
Diagnosis
Imaging
First-line: Ultrasound
- US is the imaging modality of choice
- Mass associated with BIA-ALCL: usually oval, well-circumscribed, solid, hypoechoic
- Usually not hypervascular (unlike some high-grade NHL)
- Cystic and solid mass has also been described
- Mammo: may see mass or implant contracture, but cannot see effusion
- If US inconclusive → MRI is a good second test
Board Pearl
A late seroma diagnosed > 1 year after implant placement can be indistinguishable from BIA-ALCL and may arise from hematoma, infection, capsule bleed, or rupture. Need to aspirate to differentiate.
Workup
- US-guided FNA of effusion + cytology
- If mass forming: US-guided core biopsies of mass
- PET/CT NTAP (new technology add-on payment) for mass disease ± distant disease
PET/CT Limitations in BIA-ALCL
- False negatives: effusion cell count often too low to take up radiotracer
- False positives: fibrous capsule may take up FDG from benign inflammatory response
- PET indicated only if mass-forming BIA-ALCL for evaluation of distant disease
Staging
- WHO TNM staging (not Deauville or Lugano)
- With mass/distant disease (TNM Stage II–IV): delay reconstruction
Treatment
| Disease Type | Treatment |
|---|---|
| Effusion-only | Implant + capsule removal (± contralateral prophylactic removal) |
| Mass disease, confined | Implant + capsule removal + systemic therapy |
| Distant/refractory disease | Systemic therapy (CHOP): cyclophosphamide, doxorubicin, vincristine, prednisolone |
Prognosis
- Overall survival: 97% at 3 years, 92% at 5 years (early studies)
- Presence of a mass is the only independent poor prognosticator
- No data on surveillance imaging post-treatment (doesn’t seem to affect OS)